The Hygeia Group, comprising three hospitals in Athens, Greece, joins Clinerion’s hospital network, and expands Clinerion’s Patient Network Explorer footprint in Europe. The Hygeia Group comprises three hospitals:
The Hygeia Hospital is the only hospital in Greece with a Joint Commission International (JCI) Gold Seal accreditation for quality and safety in healthcare. The group currently conducts above 80 clinical trials per year. Joining Clinerion’s Patient Network Explorer platform will bring more innovative treatments to the patients of the Hygeia Group’s hospitals and clinics, and give their physicians more options in treating their patients. The group will also gain more exposure to global clinical trials run by international pharmaceutical companies and contract research organizations. Drug developers working on innovative treatments will now benefit from access to these new geographies and clinics with strong therapeutic focus. “The strong oncology orientation of our hospitals along with the high-quality oncology staff provide a great opportunity to all stakeholders to enhance clinical trials with novel agents and combinations for our patients’ benefit,” says Mr. Andreas Kartapanis, CEO of the Hygeia Group. “The Hygeia Group has state-of-the-art infrastructure and equipment, and a roster of expert clinicians,” says Ian Rentsch, CEO of Clinerion. “This will be a great benefit to pharma companies and CROs looking to accelerate their drug trials in Greece.”
About Clinerion
Clinerion enables early patient access to innovative treatments through real-patient data solutions for clinical trial patient recruitment, real-world evidence, and market access. Clinerion's Patient Network Explorer accelerates clinical research by radically improving the efficiency and effectiveness of trial recruitment. Clinerion’s key patient data services include data-driven protocol optimization, site feasibility evaluation and patient identification. Clinerion’s solutions allow member hospitals to participate in leading-edge, industry-sponsored trials and save time in patient recruitment. They enable pharmaceutical companies to gain time and save costs by streamlining operations and leveraging strategic intelligence. Clinerion’s proprietary Big Data analytics technologies leverage real-time data from electronic health records which remain under the full control of participating hospitals. Clinerion is a global data technology service company headquartered in Switzerland. Clinerion's solutions comply with international patient privacy and data security regulations. Clinerion website:
www.clinerion.com
Clinerion’s Patient Network Explorer:
www.clinerion.com/index/OverviewOurSolutions/Clineriontechnologysolution
For more information, please contact: Le Vin Chin Head of Marketing and Communications Clinerion Ltd Margarethenstrasse 47, CH-4053 Basel, Switzerland Tel.: +41 61 865 60 54 media@clinerion.com
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.